Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against […]
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going clinical Phase I trial with the 4-1BB (CD137) drug candidate ATOR-1017, which is […]
Biomedical device passes the litmus test A University of Sydney PhD researcher is developing a cancer and serious disease-detecting biomedical probe that can be made […]
The technology used in some Covid-19 doses could facilitate different vaccines or treatments for certain cancers. These advances need the firm and constant support of […]
First Phase III study to show that a cancer immunotherapy improves disease-free survival in people with resectable early stage lung cancer compared to best supportive […]
The Chinese National Medical Products Administration (NMPA) has approved Nubeqa™ (darolutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at […]
Today, on the eve of the World Cancer Day, the European Commission is presenting Europe’s Beating Cancer Plan – a main priority in the area […]
Bayer has entered into an exclusive global license agreement with Systems Oncology, LLC, for ERSO™, a compound in pre-clinical development for the treatment of metastatic […]
Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) plus placebo met its co-primary […]
…. regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer • IMpassion031 data will be discussed with health authorities globally, […]
• Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma • […]
• ALEX study is the first global phase III study to show a clinically meaningful benefit in overall survival at five years (62.5% with Alecensa), […]
Copyright © 2022 | WordPress Theme by MH Themes
